Quarterly report · Q1

Period2023-01-01 → 2023-03-31
Filed2023-05-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥448.3bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Revenue¥1.74T2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥380.3bn2022-01-01 → 2022-03-31Cons.Revenue IFRS
Operating income¥76.8bn2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Operating income¥20.7bn2022-01-01 → 2022-03-31Cons.Operating profit loss IFRS
Profit before tax¥79.2bn2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Profit before tax¥173.0bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥31.0bn2022-01-01 → 2022-03-31Cons.Profit loss before tax IFRS
Net income (owners)¥61.4bn2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥133.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥23.3bn2022-01-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income¥62.7bn2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Net income¥24.2bn2022-01-01 → 2022-03-31Cons.Profit loss IFRS
Total assets¥3.13Tat 2023-03-31Cons.Assets IFRS
Total assets¥3.10Tat 2022-12-31Cons.Assets IFRS
Total assets¥2.89Tat 2022-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥811.5bnat 2023-03-31Cons.Liabilities IFRS
Total liabilities¥840.3bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥2.32Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥2.10Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥2.05Tat 2021-12-31dCons.Equity IFRS
Equity (owners)¥2.28Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.23Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.07Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥477.1bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥423.4bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥410.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥71.9bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥211.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥57.7bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥35.8bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥81.6bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥22.8bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥32.7bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥95.5bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥34.6bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥113.22023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥246.82022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥42.862022-01-01 → 2022-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥113.182023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥246.782022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥42.72022-01-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio72.8%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-03-31¥42.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-03-31¥33.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-03-31¥9.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-03-31¥3.7bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥9.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥9.7bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥13.0bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥4m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-03-31¥2.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥13m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥11.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥303.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥303.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥72.7bn
—segment totalrevenue2023-01-01 → 2023-03-31¥458.0bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥448.3bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥9.7bn
—segment totalsegment profit2023-01-01 → 2023-03-31¥89.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-01-01 → 2022-03-31¥39.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-01-01 → 2022-03-31¥30.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-01-01 → 2022-03-31¥8.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-01-01 → 2022-03-31¥4.1bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-03-31−¥8.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-03-31−¥8.8bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-03-31−¥11.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2022-01-01 → 2022-03-31¥7.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2022-01-01 → 2022-03-31¥7.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2022-01-01 → 2022-03-31¥3m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2022-01-01 → 2022-03-31−¥235m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2022-01-01 → 2022-03-31¥90.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2022-01-01 → 2022-03-31¥90.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2022-01-01 → 2022-03-31¥3m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2022-01-01 → 2022-03-31¥11.3bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2022-01-01 → 2022-03-31¥252.1bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2022-01-01 → 2022-03-31¥252.1bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2022-01-01 → 2022-03-31¥17.3bn
—segment totalrevenue2022-01-01 → 2022-03-31¥389.1bn
—segment totalrevenue external2022-01-01 → 2022-03-31¥380.3bn
—segment totalrevenue intersegment2022-01-01 → 2022-03-31¥8.8bn
—segment totalsegment profit2022-01-01 → 2022-03-31¥32.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 706
ItemContextValueUnit
Non current assets IFRSCurrentQuarterInstant1941538000000JPY
Assets IFRSPrior1YearInstant3102638000000JPY
Assets IFRSCurrentQuarterInstant3132041000000JPY
Trade and other payables2 cl IFRSPrior1YearInstant198356000000JPY
Trade and other payables2 cl IFRSCurrentQuarterInstant164592000000JPY
Bonds and borrowings cl IFRSPrior1YearInstant26440000000JPY
Bonds and borrowings cl IFRSCurrentQuarterInstant45532000000JPY
Lease liabilities cl IFRSPrior1YearInstant17717000000JPY
Lease liabilities cl IFRSCurrentQuarterInstant17733000000JPY
Other financial liabilities cl IFRSPrior1YearInstant3307000000JPY
Other financial liabilities cl IFRSCurrentQuarterInstant18433000000JPY
Income taxes payable cl IFRSPrior1YearInstant28340000000JPY
Income taxes payable cl IFRSCurrentQuarterInstant19867000000JPY
Provisions cl IFRSPrior1YearInstant763000000JPY
Provisions cl IFRSCurrentQuarterInstant764000000JPY
Contract liabilities cl IFRSPrior1YearInstant13376000000JPY
Contract liabilities cl IFRSCurrentQuarterInstant12725000000JPY
Other current liabilities cl IFRSPrior1YearInstant250891000000JPY
Other current liabilities cl IFRSCurrentQuarterInstant275627000000JPY
Total current liabilities IFRSPrior1YearInstant539193000000JPY
Total current liabilities IFRSCurrentQuarterInstant555276000000JPY
Bonds and borrowings ncl IFRSPrior1YearInstant93775000000JPY
Bonds and borrowings ncl IFRSCurrentQuarterInstant72684000000JPY
Lease liabilities ncl IFRSPrior1YearInstant56229000000JPY
Lease liabilities ncl IFRSCurrentQuarterInstant54633000000JPY
Other financial liabilities ncl IFRSPrior1YearInstant30515000000JPY
Other financial liabilities ncl IFRSCurrentQuarterInstant13670000000JPY
Retirement benefit liability ncl IFRSPrior1YearInstant16011000000JPY
Retirement benefit liability ncl IFRSCurrentQuarterInstant15678000000JPY
Provisions ncl IFRSPrior1YearInstant1507000000JPY
Provisions ncl IFRSCurrentQuarterInstant1513000000JPY
Contract liabilities ncl IFRSPrior1YearInstant50736000000JPY
Contract liabilities ncl IFRSCurrentQuarterInstant48166000000JPY
Deferred tax liabilities IFRSPrior1YearInstant29511000000JPY
Deferred tax liabilities IFRSCurrentQuarterInstant26223000000JPY
Other non current liabilities ncl IFRSPrior1YearInstant22787000000JPY
Other non current liabilities ncl IFRSCurrentQuarterInstant23604000000JPY
Non current labilities IFRSPrior1YearInstant301076000000JPY
Non current labilities IFRSCurrentQuarterInstant256174000000JPY
Liabilities IFRSPrior1YearInstant840269000000JPY
Liabilities IFRSCurrentQuarterInstant811451000000JPY
Share capital IFRSPrior1YearInstant81690000000JPY
Share capital IFRSCurrentQuarterInstant81690000000JPY
Capital surplus IFRSPrior1YearInstant506579000000JPY
Capital surplus IFRSCurrentQuarterInstant506724000000JPY
Treasury shares IFRSPrior1YearInstant-44858000000JPY
Treasury shares IFRSCurrentQuarterInstant-44858000000JPY
Retained earnings IFRSPrior1YearInstant1553069000000JPY
Retained earnings IFRSCurrentQuarterInstant1587375000000JPY
Other components of equity IFRSPrior1YearInstant128773000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass